Talha Badar

Dr. Talha Badar is an Assistant Professor in the Department of Hematology Oncology at Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. He serves as a member of the Acute Leukemia/Myelodysplasia Group and specializes in treating various leukemias and myeloid disorders. Dr. Badar holds multiple leadership roles including Membership on the NCCN Acute Lymphoblastic Leukemia Panel, the American Society of Hematology Publication Committee, and the Mayo Clinic Cancer Center Scientific Review Committee.

Dr. Badar completed his medical education at Jinnah Medical and Dental College (2006), followed by residencies in Internal Medicine at College of Physicians and Surgeons Pakistan (2009) and Brandon Regional Hospital (2017). He further specialized through fellowships in Medical Oncology at College of Physicians and Surgeons Pakistan (2013), Clinical Leukemia at MD Anderson Cancer Center (2015), and Hematology and Oncology at Medical College of Wisconsin (2020). He is board certified in Internal Medicine, Hematology, and Medical Oncology.

• 2020 Fellowship - Hematology and Oncology, Medical College of Wisconsin
• 2017 Residency - Internal Medicine, Brandon Regional Hospital
• 2015 Fellowship - Clinical Leukemia, University of Texas MD Anderson Cancer Center
• 2013 Fellowship - Medical Oncology, College of Physicians and Surgeons Pakistan
• 2009 Residency - Internal Medicine, College of Physicians and Surgeons Pakistan
• 2006 MBBS, Jinnah Medical and Dental College

Dr. Badar's research focuses on understanding molecular mechanisms underlying myeloid disorders and developing innovative treatment strategies. His work particularly emphasizes TP53-mutated myeloid neoplasms, FLT3-ITD mutated acute myeloid leukemia, and optimizing treatment approaches using hypomethylating agents and venetoclax. His extensive publication record demonstrates a strong commitment to translating research findings into improved clinical outcomes for patients with high-risk leukemias.

Analysis of Dr. Badar's 15 most recent publications reveals a consistent focus on precision medicine approaches for myeloid malignancies, with particular emphasis on risk stratification of TP53-mutated diseases, treatment sequencing for AML, and real-world outcomes of novel therapeutic approaches. His work frequently involves large multi-institutional collaborations through consortia such as COMMAND, CIBMTR, and ECOG-ACRIN, demonstrating his leadership in the hematology research community.

• 2019 Outstanding Fellow Research Award, Wisconsin Association of Hematology and Oncology
• 2017 Best Resident Research Award, HCA West Florida GME Consortium
• 2017 People's Choice Award, Health Corporation of America West Division
• 2015 Future Leaders Award for Clinical Research in Hematology, Celgene
• 2014 Best Abstract Achievement Award, American Society of Hematology

Dr. Badar actively mentors through his role as a faculty member at Mayo Clinic and serves on multiple review committees including the Mayo Clinic Cancer Center Scientific Review Committee and the Data Safety Monitoring Committee. His research is supported through his position as an Investigator for the National Cancer Institute and through participation in multiple clinical trials. He maintains active collaborations with national and international research groups, enhancing opportunities for trainees and junior investigators.

As a member of the Mayo Clinic Comprehensive Cancer Center's Acute Leukemia/Myelodysplasia Group, Dr. Badar leads research initiatives focused on molecular mechanisms of myeloid disorders. His laboratory work, conducted in collaboration with Mayo Clinic's advanced research facilities, investigates genetic and molecular drivers of treatment resistance in high-risk leukemias, with the goal of developing more effective therapeutic strategies for these challenging conditions.